Merck/Ariad Form Billion-Dollar Collaboration To Develop mTOR Inhibitor For Cancers

Merck’s commitment to using biomarkers, bioinformatics and diagnostics in cancer drug development was key to the deal, Ariad CEO tells “The Pink Sheet” DAILY.